Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q2 FY24 results · Jul–Sep 2023
Bliss GVS Pharma reported revenue from operations of ₹211.88 crore (up 22.9% from Q2 FY23) and net profit of ₹43.04 crore (up 169.0% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 211.88 | 172.43 | +22.9% | 159.52 | +32.8% |
| Other income | 12.60 | 2.15 | +485.8% | 5.11 | +146.5% |
| Total income | 224.48 | 174.58 | +28.6% | 164.63 | +36.3% |
| Profit before tax | 59.13 | 20.19 | +192.9% | 21.65 | +173.2% |
| Net profit for the period | 43.04 | 16.00 | +169.0% | 14.37 | +199.4% |
| Attributable to shareholders of the company | 42.31 | 13.85 | +205.4% | 14.69 | +188.1% |
| EPS, basic (₹) | 4.06 | 1.33 | +205.3% | 1.41 | +187.9% |
| Net margin (%) | 20.3 | 9.3 | 9.0 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 171.32 | 138.85 | +23.4% | 108.99 | +57.2% |
| Other income | 10.61 | 14.23 | −25.4% | 6.53 | +62.6% |
| Total income | 181.93 | 153.08 | +18.8% | 115.52 | +57.5% |
| Profit before tax | 46.07 | 35.29 | +30.5% | 10.90 | +322.4% |
| Net profit for the period | 33.89 | 25.45 | +33.2% | 7.50 | +352.1% |
| EPS, basic (₹) | 3.25 | 2.45 | +32.7% | 0.72 | +351.4% |
| Net margin (%) | 19.8 | 18.3 | 6.9 |
Consolidated
- Filed with BSE
- 17 Nov 2023, 16:30 IST
- Board meeting
- 01 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Nov 2023, 16:30 IST
- Board meeting
- 01 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE